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HSPB1 is a member of a family; small heat shock proteins (sHSP). These sHSP
have a common conserved -crystallin domain (ACD), anked by variable N- and
C- termini, whose functions are poorly understood. More than 20 disease causing
mutations in sHSPs has been described till date, most of them being dominant
missense mutations clustered around the ACD. The protein is ubiquitously ex-
pressed, participates in a number of cellular processes, and dierent pathogenic
mechanisms have been proposed. In this study, we investigated the cellular,
transcriptional and biochemical consequences of a novel heterozygous frame shift
mutation in HSPB1 p.(M169Cfs2X) predicting C-terminal truncation of the pro-
tein in a patient with dominantly inherited motor predominant axonal Charcot-
Marie-Tooth disease. We show that the truncated protein is stable in primary
broblasts, proving that the mutant mRNA is able to escape nonsense mediated
decay. Moreover, the truncated protein binds wild type HSPB1 and interferes
with its dimerization. The mutant protein translocates to nucleus and impairs the
heat tolerance of patient primary broblasts. However, the mutant HSPB1 does
not alter the global transcriptional response to heat. We suggest that ablation of
the HSPB1 C-terminus might have caused neuropathy by a dominant negative
mechanism that prevents normal HSPB1 dimerization. The impairment of the
cellular growth is mediated by the inability of truncated HSPB1 to chaperone
proteins under heat stress.
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MOPS 3-(N-morpholino)propanesulphonic acid
MPZ Myelin Protein Zero
MTMR2 Myotubularin Related Protein 2
NCBI National Center for Biotechnology Information
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NaF Sodium 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NDRG1 N-myc Downstream Regulated Gene 1 Protein
NEF2 Nucleotide Excision Repair Factor 2
NIH National Institute of Health
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RT-qPCR Reverse transcription quantitative polymerase chain
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Chapter 1
Introduction
1.1 What is Charcot-Marie-Tooth (CMT) dis-
ease?
CMT is a group of hereditary disorders that causes damage to peripheral
nerves, the nerves that transmit signals from brain and spinal cord to and
from the distal part of the body, including sensory information like touch
and pain [58]. CMT has a direct eect on nerves that control the muscles
[48]. The progressive muscle weakness may become noticeable in adolescence
or early adulthood. Clinical symptoms of CMT include length dependent
degeneration of peripheral nerves that result in weakness and waste of distal
muscles in extremities of body [3]. Symptoms normally begin in lower limbs
and moves toward the body [42]. Majority of population with CMT have
some kind of minor physical disability. According to the article published
by the US Department of Health and Human Services, NIH, on Charcot-
Marie-Tooth Disease, CMT is one of the most common inherited neurological
disorders aecting estimated 126,000 individuals in the United States and 2.6
million people worldwide [42].
1.2 General classication of CMT
Although there is no universal classication for CMT, on the basis of upper
limb motor nerve conduction velocities (MCV), we can distinguish 2 types of
CMT: demyelinating and axonal types [34, 48]. Patient with MCVs below 38
m/s are classied as CMT1 whereas patients with upper limb MCV normal
or slightly above 38 m/s are assigned as CMT2 cases [48]. The generic classi-
cation of CMT phenotype based on nerve conduction velocities is shown in
9
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the Figure 1.1. Furthermore, CMT2 patients show wider range of phenotypes
than CMT1 patients. This makes clinical diagnosis of CMT2 from CMT1
inconclusive until MCV is performed.
Mutations in dierent genes produce similar phenotypes, which leads to clin-
ical heterogeneity in patients with CMT [3]. Until now, mutations in more
than 40 genes have been associated with CMT neuropathy and related dis-
orders [3]. The varying degree of clinical phenotypes in CMT is categorized
by age dependent penetrance. The onset of disease can take place as early
as a rst decade of life depending on the inheritance of CMT, which can be
of three types: autosomal dominant, autosomal recessive or X-linked [48].
Figure 1.1: Classication of CMT phenotypes based on neurophysiology. Autosomal domi-
nant intermediate forms of CMT can share features of both CMT1 and CMT2 phenotypes.
Reproduced from [34] for the purpose of this discussion.
1.3 Dierent types of genetic inheritance
Diseases caused by mutation in single gene follow simple Mendelian or non-
Mendelian inheritance pattern, which are divided into six dierent types:
1.3.1 Autosomal Dominant
The presence of one copy of mutant alleles in cell is enough to express the
autosomal dominant condition in individuals. The mutation is located on
one of the 22 pairs of autosomes (non-sex determining chromosomes). The
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aected individual carries a copy of normal and a copy of the mutant gene
inherited usually from aected parent. Huntington disease has an autosomal
dominant inheritance pattern [43].
1.3.2 Autosomal Recessive
When individuals have two copies of the mutant allele, they express autoso-
mal recessive condition. However, the presence of a single copy of the mutant
allele is not enough to develop the condition but are classied as \carrier"
for the mutation. Sickle cell anemia is an example of such inheritance [43].
1.3.3 X-linked Recessive
X-linked conditions are the result of mutations in genes on the X chromosome
(sex determining chromosome). X-linked recessive condition develop when
there is no normal copy of the gene in the X chromosomes. Thus, males have
more chances to develop X-linked recessive condition as they have only one
copy of the X chromosome. X-linked inheritance does not have male to male
transmission and all daughters of aected male are carriers (heterozygous) of
X-linked recessive condition. Hemophilia is an example of X-linked recessive
disorder [43].
1.3.4 X-linked Dominant
X-linked dominant conditions are observed when there is a mutant copy of
the gene in one of the X-chromosome. Thus, all daughters of aected male
are aected since males have only one copy of X chromosome [43].
1.3.5 Codominant inheritance
It is the inheritance pattern observed in the ABO blood group system where
each allele inuences the trait. The combined eect of both allele results in
characteristic genetic condition [43].
1.3.6 Mitochondrial inheritance
Mitochondria are inherited in osprings only from the mother, so it is also
called maternal inheritance and is only applied to mitochondrial genes. Mito-
chondrial disorders arising from mutations in mitochondrial genes can aect
both male and female members of the family [43].
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1.4 Classes of mutation
Mutations are heritable alteration in the sequence of the genome of an or-
ganism. The organism carrying one or more such mutations is referred to
as mutant. A simple method of classifying mutations is whether or not they
are point mutations, which are the result of single base pair substitution and
insertion or deletion of few base pairs in the DNA sequence [26].
1.4.1 Base substitution mutation
A point mutation caused by substitution of one base pair with another is
known as base substitution mutation. It can be substitution of one purine
with another purine or one pyrimidine with another; commonly referred to
as transition mutation. On the other hand, the exchange of a purine for a
pyrimidine or vice versa is referred to as transversion mutation [26]. Fur-
thermore, these base substitution mutations are subclassied on the basis of
its eect on protein-coding regions of the genome.
1.4.1.1 Missense mutation
Base substitution in this type of mutation changes the codon of one amino
acid to another. Such mutation can result in mutant protein with: no de-
tectable eect, partial loss of function, gain of function, alteration of function,
altered stability or complete loss of function. Apart from these noted eects,
there are types of missense mutations referred to as silent or neutral mu-
tations, which is the result of the degeneracy of the genetic code. These
silent mutations are result of base substitution mutations caused by chang-
ing codon for an amino acid to a dierent codon for the same amino acid
ultimately resulting in unchanged protein sequence [26].
1.4.1.2 Nonsense mutation
Mutation where the codon for an amino acid is changed to one of the three
stop codons: TAG, TAA or TGA, leading to premature termination of pro-
tein synthesis is referred as nonsense mutation. These nonsense mutations
can result in partial or complete loss of protein function [26].
1.4.2 Insertion or Deletion mutation
This category of mutation is a result of insertion or deletion of a few nu-
cleotides from the DNA sequences. Usually insertion or deletion of 1, 2, 4 or
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5 nucleotides occurs in case of this type of mutation and shifts the reading
frame of the protein coding region of a gene, hence also termed as frameshift
mutation.
1.5 Genetic heterogeneity of CMT
Most of the CMT2 cases have an autosomal dominant inheritance and late
onset of the disease. However, rare and recessively inherited cases can show
an early onset [51]. Similarly, the inheritance pattern of sporadic cases is
more dicult to determine. A common pathological marker of the periph-
eral neuropathy is chronic axonal degeneration and regeneration, which leads
to a steady loss of available nerve bers [60]. The associated genes are known
to be involved in various pathways such as myelination, radial and axonal
transport, Schwann cells dierentiation, signal transduction, mitochondrial
function, endosome, protein translation and single stranded DNA break re-
pair [55]. Similarly, another important pathway involved in axon mainte-
nance is the cellular stress response pathway mediated by small heat shock
proteins (sHSPs) [58].
CMT, a motor and sensory neuropathy, is closely related to other inherited
neuropathies such as distal hereditary motor neuropathies (dHMN), which
involves only motor nerves and hereditary sensory neuropathies (HSN), which
involves only sensory nerves. The collective term used to refer all three dis-
eases is `CMT and related disorders' [48]. The genes implicated in these
diseases include structural proteins like PMP22 and MPZ associated with
myelination, GJB1 and NEFL genes involved in radial and axonal transport,
genes of signal transduction pathways (PRX, MTMR2, SBF2, NDRG1 ),
proteins related to mitochondrial function (MFN2, GDAP1 ) and molecular
chaperones (HSPB1, HSPB8 ) [55]. Most recent ndings include a CHCHD10
variant p.Gly66Val in patients with CMT2 phenotype [5], p.Gly58Arg variant
of the same gene causing a pure myopathy [2] and p.Ser59Leu causing more
aggressive amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) [8]. An illustration of this heterogeneity is represented in Figure 1.2.
1.6 HSPB1 and Charcot-Marie-Tooth Disease
HSPB1 belongs to a group of small heat shock proteins (sHSPs) assumed to
have a crucial role of protection against heat or unfolded protein stress [58].
sHSPs are ubiquitously expressed molecular chaperones with a characteris-
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tic conserved  -crystallin domain bordered by variable N- and C- terminal
regions [3]. Contrary to heat shock proteins with ATPase domain, sHSPs
cannot actively refold unfolded proteins [3]. However, they are capable of
binding unfolded proteins and keeping them in a folding competent state un-
til acted upon by ATP-dependent HSPs [3]. These sHSPs are known to form
complex oligomeric structures considered crucial for protein function. The
formation of these complex structures depend upon their phosphorylation
state and dimerization through 7 strands of ACD [9, 28]. Among the 10
sHSPs encoded by the human genome, mutations in three (encoded by genes
HSPB1, HSPB3 and HSPB8 ) have been reported to cause CMT2 or dHMN
[25, 30, 32]. Furthermore, HSPB5 variants are known to cause myopathy and
cardiomyopathy [57].
HSPB1 is a 205 amino acid protein where ACD is located at residues 87-168
[58]. The structure of HSPB1 with reported mutations is shown in Fig-
ure 1.3. Among the functions of HSPB1, protection of cell against stress
is thought to be the most important one [58]. Studies have demonstrated
the ability of HSPB1 in preventing in vitro aggregation of misfolded proteins
[54, 58]. Nuclear translocation of HSPB1 upon heat stress has been observed
in dierent cell types, which also suggests a role of HSPB1 as a chaperone
of nuclear proteins or in regulation of gene expression [14, 58].
There are about 20 disease causing mutations reported in HSPB1 and all
mutations are associated with motor neuropathy [58]. Although most of the
reported dominantly inherited mutations are clustered in ACD region, few
reported missense mutations are in non-conserved residues of the variable N-
and C- terminus of the protein [12]. It is not yet completely understood why
HSPB1 mutations lead to a disease specic to peripheral neurons despite the
gene being ubiquitously expressed. Several studies have been published where
dierent HSPB1 mutations have been studied through overexpression exper-
iments. Among them, missense mutations in the ACD region of HSPB1 have
been associated with defective dimerization, increased chaperone activity and
improved heat tolerance [4, 58]. Studies involving mutations HSPB1S135F and
HSPB1P182L discovered aggregation and altered axonal transport of neurol-
ament [1, 25, 58, 59]. These mutants had increased capacity to bind tubulin
resulting in altered dynamics of microtubules [3]. In addition to this, trans-
genic expression of these mutants in mouse neurons demonstrated decreased
acetylated -tubulin and induced defects in axonal transport [23]. Further-
more, missense mutations in the C-terminus of HSPB1 such as HSPB1P182S
and HSPB1R188W were associated with aggregation and decreased chaperone
activity respectively [16]. These studies provide us with varied in vitro eects
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of C-terminal variants.
Figure 1.2: Known disease genes for CMT and related disorders, and their proposed
pathomechanism. Reproduced from [51] for the purpose of this discussion.
1.7 Brief overview of Nonsense-mediated de-
cay and dominant negative mechanism
Nonsense-mediated mRNA decay (NMD) is a highly conserved quality con-
trol mechanism present in all eukaryotes [17]. It selectively degrades mRNAs
that have premature termination codons (nonsense codons) which, if trans-
lated, can produce a truncated protein with dominant-negative or potential
deleterious eects [17].
Premature termination codons can arise in dierent ways, which includes
random nonsense or frameshift mutations in the coding region of the DNA
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Figure 1.3: HSPB1 also known as HSP27 contains a hydrophobic N-terminal domain with
WDFP motif, an -crystallin domain at residues Glu87-Pro168 and variable C-terminal
domain from 169-205. Adapted from [29] for the purpose of this discussion.
sequences and errors in RNA splicing [17]. Studies on the mechanism of mam-
malian NMD suggest that it occurs only on newly synthesized Cap-binding
complex bound (CBC) mRNAs [17]. Mammalian NMD also involves Exon-
Junction Complex (EJC) deposited at exon-exon junctions during mRNA
splicing. The general consensus about mammalian NMD being able to dis-
tinguish between premature and normal stop codon is the presence of the
second signal downstream of the stop codon. The second signal in mam-
malian cells is dierent compared to yeast as it is delivered by an intron
downstream of the stop codon and that intron must be spliceable to initiate
NMD [17]. This suggests that normal stop codon are usually present at the
last exon. This also explains why nonsense mutations occurring in the last
exon and in transcripts lacking introns are able to escape NMD.
1.8 Introduction to microarray technology
Functional genomics attempts to answer questions about the functions of
DNA at the level of genes, RNA transcripts, and protein products such as:
monitoring the expression levels of a set of genes simultaneously under spe-
cic condition. This method of measurement of expression levels is called
gene expression analysis. Microarray technology is one of the approaches to
measure such expression levels and it involves analysis of large amounts of
data through the use of various computational methods to derive meaningful
results from such experiments [6]. The main principle behind microarray
technology is, in situ hybridization of complementary sequences.
One of the major use of microarray in measuring gene expression levels is to
compare expression of the same set of genes from cells maintained under one
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condition (Condition A) to cells under normal condition (Condition B). RNA
molecules extracted from the cells are reverse transcribed to cDNA where
RNA from dierent conditions are labelled using two uorochrome dyes Cy3
(green) and Cy5 (red) for two color microarray. For example cDNA from
condition A may be labelled with red dye and cDNA from condition B with
green dye. These cDNA are then allowed to hybridize on a single glass slide
which then compete for binding to the probes xed on the microarray sur-
face. The hybridization step is followed by scanning of the chip twice, once
for each wavelength and the nal image is generated by overlaying previous
two images. The nal image summerizes an intensity reported for every spot
for both wavelengths. The pixel intensity for each channel might be assigned
a quality score, which allows to report poor quality spots: examples of spot
quality assessment are the standard deviation of spot intensities, shape of
array image, signal-to-noise ratio [19].
One of the quality plots used to assess the quality of raw microarray data is
a MA plot. It is the plot of intensity ratio of raw microarray data where M,
in Y axis, represents the log intensity ratio for red and green channel and
A, in X-axis, represents the average log intensity. A good quality microarray
data have elongated comet shaped MA plot with large number of genes at
line M=0 representing equal intensities of the red and green channel. This
suggests most of the genes in a microarray experiment are not dierentially
expressed [19].
The quality assessment is followed by normalization, which is an essential
procedure to remove any systematic biases that do not represent any signi-
cant biological variations between samples [19]. There are several established
normalization methods such as lowess regression (local weighted scatterplot
smoothing) for intensity dependent normalization, which ts a weighted least
square curve to the MA-plot and is subtracted from original log-ratio to ob-
tain normalized log-ratio [19]. Similarly, another normalization approach is
quantile normalization, which aims to make similar distribution of inten-
sities across the set of arrays [19]. Overall, these normalization methods
preserve the interesting variations while trying to remove unnecessary tech-
nical variations [19]. After normalization, the result of two color microarray
experiments is reported as fold-change between channel intensities for each
spot, which is the measure for mRNA abundance across two samples. The
schematic experimental process of microarray is shown in Figure 1.4.
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1.9 Transcriptional regulation and its com-
plexity
The combination of transcription factors binding to promoter regions of genes
regulate key functional processes of cells through regulation of gene expres-
sion. Thus, analysis of the promoter regions of genes expressed under specic
conditions can be useful to describe disease-association of such genes based
on the phenotypic properties [40].
Figure 1.4: Representation of microarray experiment. Reproduced from [15] for the pur-
pose of this discussion.
Transcription is a series of complex reactions, which is inuenced by many
regulatory signals. Furthermore, transcription is also context dependent as
every regulatory signal is dened by unique anity of DNA-binding molecules,
transcription factors and histones. The interaction of these with DNA result
in the formation of unique transcriptional machinery that leads to a tran-
scriptional product [45].
Promoter region is upstream of the coding sequence where assembly of pre-
initiation complex occurs, which helps to position RNA polymerase II com-
plex at the transcription start site (TSS). The region where RNA polymerase
II is recruited is called the core promoter and the rest of the region corre-
sponds to transcription factor binding sites (TFBS). Absence of specic tran-
scription factors at TFBS shuts down the activity of these promoter regions
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in eukaryotes [45].
1.9.1 In Silico promoter analysis and prediction of reg-
ulatory motifs of functional relevance
The amino acid sequence of a protein is uniquely determined by the coding
region of a gene. On the other hand, the regulatory sequences that are
present at untranslated regions of the gene have indirect, non-linear and
context dependent relationship with transcriptional regulation, for example
in determining their transcription prole [45]. Regulatory regions play an
important role in gene function and being able to predict them under specic
condition will provide us with an additional insight on genotype-phenotype
correlation. In most of these cases, co-regulation is the result of activation of
common transcription factors interacting with cis-regulatory motifs present
in their promoter region [45]. A regulatory pattern obtained from a group
of transcription factor binding sites after alignment is usually represented as
consensus sequence or a Position Weight Matrix (PWM).
1.9.2 Consensus sequence
It is the representation of most frequent residues of either nucleotide or
amino acid calculated using distribution of those residues in the sequence
alignment. Consensus sequence represents a conserved sequence motif in
multiple sequence alignment and shows which residues are conserved and
which residues are variable [52]. The motif is represented as letters of the
IUPAC code, where the highest nucleotide composition of each column of the
alignment is assigned for each position of the consensus sequence [45]. For ex-
ample, in a consensus sequence notation for DNA sequence: TATAAT, each
base occupies corresponding position even though the percentage of occur-
rence of `T' and `A' at all positions is not 100%. Thus, a consensus sequence
does not take into account the relative frequency of occurrence of nucleotide.
There exists an alternative method to represent a consensus sequence called
sequence logo, which also considers the relative frequency of occurrence of
nucleotides at that position. Sequence logo is the graphical representation
of consensus sequence where the size of the symbol is directly proportional
to the frequency of the nucleotide in the multiple sequence alignment. The
more conserved residue has the larger symbol [52]. The consensus sequence
of KLF4 motif is represented in Figure 1.5.
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Figure 1.5: Sequence logo of KLF4 (MA0039.2) representing consensus sequence of KLF4
binding site in the promoter region.
1.9.3 Position Weight Matrix
It is a matrix constructed from a set of aligned sequences which are known to
bind a common transcription factor, where each element is proportional to
the observed count of nucleotide at the corresponding position [18]. The rst
step in construction of PWM from a set of aligned sequences is computing
a matrix with a frequency of nucleotide at each position. The elements of
resulting matrix can be interpreted as probability, by dividing each occur-
rence frequency by the number of sequences used to generate the matrix [27].
An illustrative example of calculation of PWM from set of aligned sequences
is shown below. An example of aligned sequences from 5'! 3' is given below:
GAGGTAAAC
TAGGTCATT
AAGGTAAGT
CAGGTATAC
ACAGTCAGT
TCCGTAAGT
TGTGTGAGT
The frequency matrix for the above aligned a set of sequences is given by ma-
trix M, where each row in matrix M represents frequency of the nucleotides
A, C, G, T respectively in the corresponding position of the alignment rep-
resented by columns in the matrix M. For instance, M[1,1]=2 represents the
frequency of A at position 1 of the sequence.
M =
2664
2 4 1 0 0 4 6 2 0
1 2 1 0 0 2 0 0 2
1 1 4 7 0 1 0 4 0
3 0 1 0 7 0 1 1 5
3775
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Similarly, above matrix M can be modied to represent the probability of
nucleotide occurrence by dividing each element of M by the number of se-
quences (N=7).
M =
2664
0:29 0:57 0:14 0 0 0:57 0:86 0:29 0
0:14 0:29 0:14 0 0 0:29 0 0 0:29
0:14 0:14 0:57 1 0 0:14 0 0:57 0
0:43 0 0:14 0 1 0 0:14 0:14 0:71
3775
PWM are generally transformed using a background model and represented
as log likelihoods [27]. A simplest background model is to assume equally
likely occurrence of nucleotides in the data, which would be 0.25 (4 dierent
DNA bases) for nucleotides and 0.05 (20 dierent amino acids) for amino
acids. The log likelihoods for PWM is calculated as:
M = ln

Mi;j
B

(1.1)
Transformation of above matrix M using Equation 1.1 gives:
M =
2664
0:13 0:83  0:56 1 1 0:83 1:23 0:13  1
 0:56 0:13  0:56 1 1 0:13  1  1 0:13
 0:56  0:56 0:83 1:39  1  0:56  1 0:83  1
0:54 1  0:56 1 1:39  1  0:56  0:56 1:05
3775
In order to avoid the value of `-1' in PWM generated from a small number
of sequences, pseudocounts are often applied while calculating PPMs [44].
Furthermore, background model can also be adjusted according to the ge-
nomic region. For example, a frequency of bases G and C can be empirically
increased for GC rich region. Using these normalized frequencies of the four
nucleotides, PMW model reects binding preferences at each position. Thus,
a score can be calculated using the values observed at each corresponding nu-
cleotide position which is proportional to the binding energies [45]. Several
databases are available which record the PMWs of specic transcription fac-
tors such as JASPER, TRANSFAC. On the other hand, pattern discovery
detects common motifs in a group of unaligned sequences. There exist many
methods for prediction of relevant TFBSs in a set of sequences and are based
on word counting, pattern matching (PWM) or pattern discovery algorithm.
Although prediction of single TFBS might have a higher false positive rate,
predicted overrepresentation of TFBS are likely to have functional relevance
as this method is highly dependent on the background model [45].
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1.10 HSPB1 mutation explored in this study
In this study, I investigate a novel heterozygous HSPB1 mutation in a patient
with dominantly inherited motor predominant axonal Charcot-Marie-Tooth
disease: a unique frame shift mutation predicting ablation of the entire C-
terminal domain of the protein p.(M169Cfs2X) and a missense mutation
HSPB1R127L. Similar truncated variants were also described earlier, but the
stability of putative truncation was not investigated [35, 50]. Thus, the
mechanism of these truncations remained obscure. Furthermore, missense
mutation HSPB1R127L is studied together with the truncated variant, but
dropped later in the study as broblasts of this missense variants behaved
normally and produced no clear phenotypes. In vitro study of mutant pro-
tein was carried out using patient derived primary broblast. This study
demonstrates the stability of truncated HSPB1 and its ability to bind its
wild type counterpart, suggesting a dominant negative eect, which impairs
the ability of patient cells to cope with the stress.
1.11 Aims of this study
The identication of a novel heterozygous mutation (p.M169Cfs2X) predict-
ing ablation of entire C-terminus of the protein HSPB1 provided us with an
opportunity to investigate the cellular, transcriptional and biochemical con-
sequences of mutation in patient derived primary broblasts as the disease
model. Through this project, I attempted to nd out answers for at least
some of the questions listed below:
1. Is the truncated protein stable in patient broblasts and is the dimer-
ization aected?
2. Do the truncated proteins translocate to the nucleus upon heat stress?
3. Does the truncated protein aect the transcriptional heat stress re-
sponse?
4. Are the patient cells sensitive to heat stress?
5. What is the role of HSPB1 in transcriptional heat stress response?
6. Does the transcriptional prole of the HSPB1 patient cells dier from
that of control cells?
7. Are there common transcription factors co-regulating genes of specic
pathway in up-regulated and down-regulated genes?
Chapter 2
Materials and Methods
After identifying the novel truncated HSPB1 (HSPB14C-term) mutant, we
were interested in studying its functional eect and pathways that were al-
tered in the patient. The rst step was to elucidate the stability of the
truncated HSPB1 followed by other experimental and computational meth-
ods. This section discusses the details of the methods used in the project.
The general workow of the project is outlined in the Figure 2.1
2.1 Cell Culture
Control and patient (HSPB14C-term) broblasts were cultured at 37C in
DMEM supplemented with 10% FBS, L-glutamine, Pen-Strep, and Uridine
in the presence of 5% CO2 in all experiments unless specied.
2.2 Western Blotting
For western blotting, lysis buer RIPA (1x PBS, 1% Nonidet-P-40, 0.5%
sodium deoxycholate, 0.1% SDS) was used to prepare whole-cell lysates. Cells
were suspended in 50 Mm Tris-HCl (pH 8.0), 10% glycerol, 1% Nonidet P-40,
150 mM NaCl, 5mM NaF, 5uM ZnCl2, 1 mM Na3VO4, 10mM EGTA and
complete protease inhibitor. Then, the cells were lysed on ice for 10 minutes
and centrifuged and pellet discarded. The supernatant was boiled in non-
reducing loading buer (250 mM Tris-HCl, pH 6.8, 10% SDS, 30% glycerol,
0.02% bromophenol blue) for 5 minutes. For nuclear enrichment, cells were
rst homogenized by passing through 22G syringe needle 8-12 times in a
buer (0.3M sucrose, 1mM EGTA, 5mM MOPS, 5mM KH2PO4 and com-
plete protease inhibitor) at pH 7.4 followed by centrifugation at 6500 rpm
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for 15 minutes at 4C. The supernatant and pellet were collected as cytosolic
fraction and nuclear fraction respectively. Furthermore, nuclear fractiona-
tions were done for both non-treated cells and cells subjected to 45C heat
shock for 1 hour. Similarly, for extracellular HSPB1, patient and control
broblasts were grown in 6 well plates for 24 hours and 50 l of the medium
from the plates were transferred to 1.5 ml centrifuge tubes and centrifused
at 1500 rpm for 15 minutes. Supernatants from each tube were transferred
to new ones and stored at -80C until use. Proteins were separated by SDS-
PAGE following the standard protocol.
Before transfer of proteins to a nylon membrane, the membrane was pre-
treated with methanol for 10 seconds and washed with milliQ water for 2
minutes and kept in semi-blot solution (2.9 g glycine, 5.8 g Tris-base, 3.75
ml 20% SDS in 800 ml water and 200 ml methanol). For transfer of pro-
teins from gel to membrane; three Whatman paper, SDS-PAGE gel, nylon
membrane followed by another 3 Whatman paper were stacked in transfer
apparatus and ran for 1 hour and 10 minutes at 50 mA (milliampere). Af-
ter completion of the transfer, the membrane was blocked with 5% milk for
1 hour and incubated with primary antibody overnight in a shaker at 4C.
After the incubation with primary antibody, the membrane was washed with
Tris-buered saline with Tween 20 (TBST) solution 3 times in a shaker for
15 minutes, followed by incubation with secondary antibody for 1 hour at
room temperature and washing with TBST as before.
For visualization, the membrane was incubated in dark with 1.5 ml of sub-
strate (peroxide solution) and 1.5 ml of enhancer (luminol) for 5 minutes and
imaged using BioRad Chemidoc
TM
.
Antibodies used were: anti-HSPB1 (18284-1-AP; Proteintech, Chicago, IL,
USA), anti-GAPDH, anti-histone H3 and anti-tubulin (2118, 4499 and 2146
respectively, Cell Signaling Technology, Danvers, MA, USA). The general
experimental set up for protein transfer in western blot is shown in Figure
2.2.
2.3 Immunocytochemistry
Control and patient (HSPB14C-term) broblasts were cultured according to
a standard method. Media was removed and the cells were rinsed 3 times
with phosphate-buered saline (PBS). Then were xed on glass slides with
4% paraformaldehyde for 10 minutes and again rinsed with PBS 3 times.
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Cell culture and protein extrac-
tion for western blot experiments
Western blot of whole cell lysate, cytoplasmic
and nuclear fraction to examine the stability and
nuclear translocation and HSPB1 respectively
Observe the cellular distribution of HSPB1 before
and after heat treatment with immunocytochemistry
Gene expression study using Illumina HumanHT-
12 v4 Expression BeadChip of control and patient
broblast before and after 30 minutes of heat treatment
for observing changes in transcriptional heat shock
response between control and patient broblasts
Data analysis for identifying dierentially ex-
pressed genes before and after heat treatment
Validation of the microarray data using RT-qPCR
Pathway analysis and in-silico promoter anal-
ysis using top up- and down-regulated genes
from the microarray data using PANTHER and
Motif-based sequence analysis tool (MEME Suite)
Stress tolerance assay of control, patient and
HSPB1-/- broblasts using continuous cell
growth monitoring before and after heat shock
Compiling Results and nal analysis
Figure 2.1: Work ow of the project
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Figure 2.2: A set up for protein transfer in western blot. Source [46]
Cellular permeabilization was done by incubating the cells for 15 minutes
with 0.2% Triton X-100 and were washed three times with phosphate-buered
saline with Tween 20 (PBST) (0.1% Tween 20). To prevent unspecic bind-
ing of antibody, the slides were blocked with 3% BSA/PBST for 2 hours
at room temperature. Primary antibody dilutions were prepared in 3%
BSA/PBST at a ratio of 1:1000. The cells were incubated with primary an-
tibody at room temperature for 12 hours in a shaker and were covered with
foil to prevent drying. The slides were then washed three times with PBST
for 10-15 minutes each. Furthermore, secondary antibody dilutions were also
prepared in 3% BSA/PBST in the ratio 1:2000 and incubated at room tem-
perature for 1 hour and washed three times with PBST for 10-15 minutes
each. After nal wash, cells were mounted with 30l VECTASHIELD R and
coverslips were dropped on top of mounting media and left for 1 hour in dark
to dry. Same antibodies were used as in western blotting and DAPI was used
for nuclear staining. The cells were visualized using Axioplan 2 uorescent
imaging unit.
2.4 Gene Expression Microarray
Control and patient (HSPB14C-term) broblasts were subjected to heat shock
for 30 minutes at 45C and total RNA was extracted from both treated and
untreated cells using Nucleospin R total RNA extraction kit according to the
protocol specied by the manufacturer using three independent replicates.
The gene expression proling was performed using Illumina HumanHT-12
v4 BeadChip. The les obtained from GenomeStudio were read by R using
lumiR() function from lumi package [21] and annotated using latest annota-
tion le from Illumina. The data were corrected for background adjustment
and normalized using quantile normalization method implemented in func-
tion lumiExpresso() of lumi package. GenomeStudio outputs intensity values
for each probe together with the detection p-value. Probes with detection
p-value  0.01 were selected for further analysis. The details of the design of
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the microarray experiment is shown in the Table 2.1. We were interested in
realizing the dierential expression between patient and control at untreated
condition, P0-C0 and at treated condition, P30-C30. Similarly, response
of control to treatment (C30-C0) and response of the patient to treatment
(P30-P0) were also evaluated. Test for dierential expression was performed
in R using lmFit() function implemented in limma package [49] followed by
topTable() function, with sort by `none' option to return the list of all genes
together with their associated log ratio and adjusted p-value. By default the
method of Benjamini-Hochberg was used to correct for multiple testing, by
calling the p.adjust() function.
Array Number Sample Name Sample Type Explanation
9989522057 A P 0 1
P0
Patient,
no heat shock
9989522057 B P 0 2
9989522057 C P 0 3
9989522057 D C 0 1
C0
Control,
no heat shock
9989522057 E C 0 2
9989522057 F C 0 3
9989522057 G P 30 1
P30
Patient,
with 30 min
heat shock
9989522057 H P 30 2
9989522057 I P 30 3
9989522057 J C 30 1
C30
Control,
with 30 min
heat shock
9989522057 K C 30 2
9989522057 L C 30 3
Table 2.1: Microarray experiment design.
2.5 Gene set enrichment analysis for dier-
entially expressed genes
This test was performed on the list of top dierentially expressed genes in
order to identify if a particular class of genes (e.g., Gene Ontology biolog-
ical processes or the PANTHER pathways) is overrepresented or underrep-
resented. PANTHER program [37] was used to perform this analysis and
was carried out on genes with either two fold up- or down-regulation of gene
expression and p-value  0.01, which is equivalent to log-ratios of +1 or -1
respectively. The reference list used for the analysis contained all the genes
from Illumina HumanHT-12 v4 BeadChip. The PANTHER program then
applied the binomial test for each PANTHER class to determine whether
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there is an overrepresentation or underrepresentation of genes in the test set
relative to the reference set. The `expected value' in the analysis was the
number of genes that would be present in the test list based on the reference
list. For instance, among approximately 47,000 genes in Illumina HumanHT-
12 v4 BeadChip, 5,000 maps to GO term cell cycle. Therefore, 0.1% (5,000
divided by 47,000) genes in reference list were involved in cell cycle. If the test
list uploaded to the PANTHER contains 10,000 genes, 10 genes (10,000 mul-
tiplied by 0.1%) would be expected to be involved in cell cycle. Now, for any
biological process, if more genes were observed in the test list than expected,
there was an `overrepresentation' (+) of genes involved in the process. If
fewer genes were observed than expected, there was an `underrepresentation'
(-). A p-value was calculated to determine if the overrepresentation (+) or
underrepresentation (-) was signicant or not. The statistical method used
to perform the overrepresentation test was a binomial test.
2.6 In-Silico promoter analysis for identica-
tion of over-represented motifs in upreg-
ulated and downregulated genes
The aim of this analysis was to identify the putative upstream regulatory
elements that might have caused the changes in the gene expression levels
observed between the patient (HSPB14C-term) and the control broblasts.
The rst step in this analysis was to lter the up-regulated and down-
regulated genes independently based on the adjusted p-value and fold change
cut-o. The data was generated to capture early responding genes to heat
shock. Thus, it is expected that those genes would vary widely among the
other genes. However, we also wanted to capture genes with intermediate
changes for the promoter analysis, as it is known that not all mRNAs are
translated into proteins. Similarly, some mRNAs are more stable compared
to others, thus requiring less transcription [11]. These motivated us to set
a less stringent criterion to lter genes for promoter analysis. I chose ad-
justed p-value cut-o  0.01 and log ratio  1.75 for up-regulated genes and
log ratio  -1.75 for down-regulated genes. The promoter sequences of all
genes in the list were extracted using EPD database [20], as it contains ex-
perimentally determined transcription start site (TSS) and is an annotated
non-redundant database of eukaryotic POL II promoters. For all the genes,
sequence between -499 to 100 bp relative to TSS was extracted, which cor-
responds to transcription factor binding sites (TFBS) at short distance from
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the TSS. For genes with splicing variants, promoter sequences from all vari-
ants were extracted, as we had no information regarding the variant level
expression of genes from the microarray data. Motif enrichment analysis
(MEA) was implemented using the AME tool [36] and CentriMo algorithm
[7] of the MEME suite against known TF matrices in JASPER CORE (2014)
vertebrates database.
The MEA method is based on the expectation maximization (EM) algo-
rithm. The algorithm uses motif model represented as a position weight
matrix (PWM) and both the motif model and its locations in the sequences
are optimized iteratively. The choice of background aects the accuracy of
the AME algorithm [36]. I performed the analysis with shued input se-
quences as control sequences for the analysis. Furthermore, I performed the
same analysis with CentriMo, which uses PWM to scan the set of equal-
sized peak regions (promoter sequences). It declares at most one binding site
in each equal-sized peak region and discards regions with no declared site.
Thus, each remaining region contains one site and the null model assumes the
site to be uniformly distributed within the region. This assumption implies
that a binomial model can be applied to the number of sites in the central
region. This will account for the background choices as anking sequence
can be used as background model.
2.7 Total RNA extraction and RT-qPCR for
validation of micorarray data
Total RNA from 3 controls, patient (HSPB14C-term) and HSPB1-/- brob-
lasts was extracted using the same kit used for total RNA extraction for
microarray experiment according to the protocol specied by the manufac-
turer. The knockout cell line of HSPB1 was generated using CRISPR-Cas
genome editing vector for HSPB1 provided by Horizon's free CRISPR Guide
RNA program. Concentration of total RNA was measured using NanoDrop
spectrophotometer. Among the top up-regulated and down-regulated genes,
11 genes were randomly selected for validation through RT-qPCR. Primers
for all the genes were designed using the Primer-Blast tool from NCBI.
2.7.1 cDNA synthesis
530 ng of total RNA was used as a template for the reverse transcription
in 20l volume. The rst step was to incubate total RNA with random
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hexamer primer for 5 minutes at 65C. The combined volume of water and
RNA (x and y in Table 2.2) had 530 ng of total RNA. This incubation was
followed by addition of 10l of reverse transcription buer and 2l of reverse
transcription mix (Thermo Scientic DyNAmo cDNA Synthesis kit, F-470L)
and running a PCR according to the conditions mentioned in Table 2.3.
Volume (l)
Water x
RNA y
Random Primer 1
Total 8
Table 2.2: Random Priming
Temperature Time (Minutes)
25C 10
37C 60
85C 5
Table 2.3: First strand synthesis
2.7.2 RT-qPCR
The template from above cDNA synthesis step was diluted to get 25 ng of
cDNA in 5 l of water. The composition of the reaction mixture and reaction
conditions are shown in Table 2.4 and Table 2.5 respectively.
Volume (l/well)
cDNA 5
2 Syber 10
F-Primer 1
R-Primer 1
Water 3
Table 2.4: RT-qPCR Mix
Temperature Time Cycles
95C 7 min
95C 10s
60C 30s !
Table 2.5: Reaction condition. Blue color
and arrow indicate the cycle is repeated 40
times.
2.8 RT-qPCR of heat shock genes in control,
HSPB14C-term and HSPB1-/- broblast be-
fore and after heat shock
To assess the aect of HSPB1 in the transcriptional heat response in pa-
tient broblasts, it was essential to have a cell model with total knockout of
HSPB1. Total RNA from HSPB1 knockout broblasts along with three con-
trol broblasts and patient (HSPB14C-term) broblasts was extracted at nor-
mal condition and after 1 hour of heat treatment at 45C using Nucleospin R
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total RNA extraction kit according to the protocol specied by the man-
ufacturer. As discussed in the Section 1.6, HSPB1 does not participate in
the active refolding of proteins, but can act as a substrate holder for ATP
dependent HSPs such as HSP70. DNAJB1 is known to interact with HSP70
and stimulate its ATPase activity and HSPA6 is a homolog of HSP70. Thus,
HSPB1 might inuence their activity. These genes (HSPA6 and DNAJB1)
were selected to test the role of HSPB1 in transcriptional heat shock re-
sponse, as these genes were also seen to be up-regulated in both control and
patient during heat shock in the microarray experiment. Primers for both
genes were designed using Primer-Blast from NCBI. For the RT-qPCR ex-
periment, GAPDH was used as reference gene as it had a stable expression
in (HSPB14C-term), control and HSPB1-/- broblasts. 1 mg of total RNA was
used as a template for cDNA synthesis and RT-qPCR. Both were performed
using the protocol specied in Subsection 2.7.1 and 2.7.2.
2.9 Stress Tolerance Assay
Control, patient (HSPB14C-term) and HSPB1-/- broblasts were cultured at
37C and 5% CO2 in a 12 well plate with triplicates at a cell density of 6.6 x
103cells/well. The medium used was DMEM supplemented with 10% FBS,
L-glutamine, Pen-Strep, and Uridine. The cells were allowed to grow for 24
hours and moved to Cell-IQ system (CM Technologies, Tampere, Finland)
and followed for 24 hours with 49 regions imaged every 3 hours. Medium
was changed and cells were subjected to heat shock for 2 hours at 45C and
returned to normal condition and followed for 24 hours with the same 49
regions imaged every 3 hours. The images were analyzed using the Cell-IQ
image analysis software provided by CM Technologies. The software was
trained manually to detect broblast cells in the image. Total cells, before
and after heat shock, were counted at each time point to observe the growth
curve of cells. Statistical signicance in growth rate between cell types was
tested using two-way ANOVA.
Chapter 3
Results
This chapter mainly focuses on the description of the results obtained from
the experimental methods described in Chapter 2.
3.1 Truncated HSPB1 is stable and is able to
dimerize with its wild type counterpart
Errors in gene expression that results in mRNA transcripts with premature
stop codons are eliminated by a NMD pathway discussed in the Section
1.7. To assess if the truncated HSPB1 is stable or not, I ran a SDS-PAGE
on lysates of primary patient broblasts. Although patient broblast with
missense mutation HSPB1R127L had similar amounts of full length HSPB1,
HSPB14C-term broblast showed two bands while reacting with anti-HSPB1.
The two bands in HSPB14C-term broblast correspond to full length (27
kDa) and truncated HSPB1 (23 kDa) respectively as shown in Figure 3.1.
It was known to us that HSPB1 dimers are resistant to denaturation. How-
ever, they dissociate when treated by reducing agents like SDS [4]. Thus,
to realize if truncated HSPB1 could form homodimers and heterodimer with
itself and wild type, I performed western blots under non-reducing conditions
that would allow us to visualize oligomers of HSPB1.
According to protein bands observed in the Figure 3.2, the control brob-
lasts showed bands that correspond to the wild type 27 kDa monomer and
the wild type50 kDa dimer. However, in the same blot the HSPB14C-term -
broblasts showed two additional faint bands between the normal sized monomer
and dimer. These bands can be explained as heterodimers formed by a wild
type and a mutant protein, and homodimers formed by two mutant pro-
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teins respectively. Furthermore, from Figure 3.2 we can also distinguish that
the total abundance of wild type HSPB1 homodimer was relatively less in
HSPB14C-term broblasts when compared to control broblasts. This result
suggests HSPB14C-term protein binding to wild type HSPB1 protein exerted
a possible dominant negative eect resulting in a decreased abundance of
wild type homodimer [58].
Figure 3.1: Truncated HSPB1 was stable under reducing conditions as shown by west-
ern blot followed by immunodetection of RIPA lysates of primary broblasts with anti-
HSPB1 antibody. The gure is a representative blot from control (C), HSPB1R127L (P1)
and HSPB14C-term (P2) broblasts respectively. HSPB14C-term (P2) broblasts shows
two bands 27 kDa corresponding to wild type HSPB1 and 23 kDa corresponding to
truncated HSPB1. GAPDH was used as a loading control.
Figure 3.2: Western blots under non-reducing conditions. For control broblasts (C1-3) a
band at 27 kDa represents the wild type monomer and a band at 50 kDa represents
the wild type dimer. In HSPB14C-term broblasts (P), in addition to above two bands,
two additional fainter bands (arrowheads) can be observed, which represents heterodimers
formed by wild type and truncated HSPB1 and homodimers formed by two truncated
HSPB1. The HSPB1 knockout broblast (KO) does not show any bands corresponding
to HSPB1. GAPDH was used as loading control.
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3.2 Truncated HSPB1 (HSPB14C-term) translo-
cates normally to nucleus
In the cells stressed with mild heat (43C), HSPB1, previously known as
HSP25 or HSP27, changes its cellular location, forming characteristic gran-
ules in the nucleus [14]. To observe if there was any nuclear translocation
activity of truncated HSPB1, I used western blot of nuclear enriched fraction
after heat shock and immunocytochemistry methods as described in Chap-
ter 2. From the Figure 3.3 (A) it was clear that HSPB1 translocates to the
Figure 3.3: HSPB1 translocated to the nucleus under heat stress. Figure A is a repre-
sentative immunocytochemistry of primary broblasts with anti-HSPB1 antibody (green)
and Figure B is a western blot performed after nuclear enrichment. It can be observed
that, fraction of cytoplasmic HSPB1 translocated to the nucleus at 45C in control (WT),
HSPB14C-term and HSPB1R127L broblasts. Nuclei are represented as dotted lines and
Bars = 20 m. (B) After Nuclear enrichment and Western blotting, there was increased
abundance of HSPB1 in the nucleus (Nucl) compared to the cytoplasm (Cyt) at 45C.
Histone H3 protein was used as a nuclear loading control, and GAPDH as a cytoplas-
mic loading control. It can be realized from the image that the HSPB14C-term protein
translocates to the nucleus and is detectable after heat stress.
nucleus upon heat stress as the nuclear region (shown in dotted circles) were
heavily stained in green after heat stress. Similarly, the presence of trun-
cated HSPB1 in the nuclear fraction from the western blot conrmed that
both wild type and truncated HSPB1 translocated to the nucleus. From the
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Figure 3.3 (B), it is evident that truncated HSPB1 is enriched in the nu-
clear fraction of patient broblasts (HSPB14C-term). These results support
that there is no defect in nuclear translocation of HSPB1 in patient brob-
lasts. Furthermore, cytoplasmic and nuclear HSPB1 concentration, HSPB1
nuclear translocation upon heat stress of HSPB1R127L broblasts were sim-
ilar to that of control. Thus, these broblasts were not included in further
analysis.
3.3 Gene expression analysis of control and
patient (HSPB14C-term) broblasts
The results from nuclear translocation of truncated HSPB1 raised an impor-
tant question; does it inuence global transcriptional heat response in patient
broblasts? To answer this, we decided to perform a gene expression analysis
between control and patient broblasts. The experimental design for the mi-
croarray was discussed in Chapter 2. The results of the dierential expression
analysis of patient vs. control without heat treatment (P0-C0) and patient
vs. control with heat treatment (P30-C30) at dierent p-value and log ratio
cut-os are shown in the Table 3.1. We observed 49 and 47 dierentially
expressed genes for P0-C0 and P30-C30 at log ratio cut-o between -2 and 2
respectively. There were 44 common genes dierentially expressed between
two conditions. Similarly, there were 73 and 71 dierentially expressed genes
at log ratio cut-o between -1.75 and 1.75 with 68 common genes dieren-
tially expressed between two conditions. This result suggests similar global
transcriptional prole of patient vs. control under normal (P0-C0) and 30
minute heat treatment (P30-C30) condition, as there were a similar number
of genes dierentially expressed and most of the dierentially expressed genes
were common to both conditions.
Cut-o P0-C0 (A) P30-C30 (B) A \ B
p-value  0.01 4050 2472 2241
p-value  0.01,
-2  logFC  2 49 47 44
p-value  0.01,
-1.75  logFC  1.75 73 71 68
Table 3.1: Numbers of signicantly dierentially expressed genes with dierent cut-o
values between the two comparisons. A represents the condition P0-C0, B represents
condition P30-C30 and A \ B represents number of common dierentially expressed genes
between two conditions.
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3.4 Pathway enrichment
Pathway analysis was performed on genes with either two fold up- or down-
regulation in gene expression and p-value  0.01, which is equivalent to
log-ratios of +1 or -1 respectively. This analysis was performed with an
assumption that genes with small changes in expression levels can have af-
fect at the pathway level through synergy. As discussed in the Section 2.5,
pathway analysis using PANTHER revealed enrichment of negative regula-
tion of apoptotic processes, macrophage activation, cellular defence response
and immune system process. Enrichment of these pathways suggests early
response of cells to stress and eect on growth of cells. As expected, our
analysis identied the same enriched pathways both in the treated and in
the untreated condition because the top genes under both conditions had
high overlap. The Table 3.2 shows pathways enriched only under untreated
condition (P0-C0) along with their fold enrichment and p-value.
An interesting nding was enrichment of extracellular matrix proteins as
shown by enrichment of cell-cell adhesion. Few previous studies have pro-
vided data with the extracellular release of HSPB1, its possible involvement
in immunogenic function and its ability to chaperone antigenic peptides
[33, 47]. Furthermore, increased serum HSPB1 was observed in cancer pa-
tients [33]. However, the role of soluble HSPB1 was not discussed. Similarly,
it was also reported that HSPB1 secretion was increased in macrophages by
estrogen and HSPB1 was found within secretary lysosomal-like vesicles [47].
In our case, the presence of two kinds of HSPB1 in patient cells raise further
questions such as: Can both truncated and wild type HSPB1 be secreted?
If yes, how do they aect the normal function? I was not able to investigate
these questions since I could not detect the secreted HSPB1 from conditioned
medium by the western blot following the described protocol [33].
3.5 Role of HSPB1 in transcriptional heat re-
sponse
To evaluate the response of control (C0-C30) and response of patient (P0-
P30) broblasts to heat treatment I analyzed the dierences in the expression
levels of genes after heat shock for both the patient and the control samples.
The result of the analysis is shown in Table 3.3. This analysis resulted in
5 dierentially expressed genes at p-value  0.01 and -1.75  logFC  1.75
under both condition suggesting patient and control broblasts have similar
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transcriptional heat shock response. The 5 common dierentially expressed
genes were encoding proteins for heat shock and stress response (DNAJB1,
EGR1, FOS, HSPA6 and HSPA7 ).
Pathway
Genes in
Background
Genes in
Test
Expected
Fold
Enrichment
p-value
macrophage activation 264 17 4.28 3.97 4.36E-04
negative regulation
of apoptotic process
182 11 2.95 3.73 4.79E-02
cell-cell adhesion 494 27 8.01 3.37 1.15E-05
cellular defense
response
372 19 6.03 3.15 2.94E-03
cell adhesion 858 39 13.91 2.8 1.68E-06
response to stimulus 1590 56 25.77 2.17 5.74E-06
immune system process 1647 56 26.69 2.1 1.87E-05
Table 3.2: Enriched pathways obtained after pathway analysis of gene-set from top up-
and down-regulated genes of Patient Vs Control without heat treatment (P0-C0).
As discussed in Section 2.8, HSPB1 does not actively refold misfolded pro-
teins, but can act as a substrate holder for ATP dependent HSPs such as
HSP70. Since DNAJB1 and HSPA6 are ATP dependent HSPs, absence of
HSPB1 might inuence their activity. To further evaluate the role of HSPB1
in transcriptional response, the cells were exposed to heat stress for a longer
period of time (1 hour) and expression levels of the two heat shock proteins:
DNAJB1 and HSPA6 were quantied using RT-qPCR. From the Figures
3.4 and 3.5, it can be observed that although relative expression levels of
both genes in HSPB1-/- cells are lower compared to control, it is not signi-
cant. This suggests HSPB1 might not have participated in early heat shock
response of patient broblasts.
3.6 Patient and HSPB1-/- broblast are sen-
sitive towards heat stress
As described in Section 2.9, it was possible to assess the eect of heat treat-
ment on the growth rate of control, patient (HSPB14C-term) and HSPB1-/-
broblasts using continuous video monitoring through Cell-IQ system. The
images captured immediately after heat shock were out of focus hence they
were not included in the analysis. The number of live cells before and af-
ter heat shock of control, patient (HSPB14C-term) and HSPB1-/- broblasts
revealed signicant dierence in growth rate between control and patient
(HSPB14C-term) broblasts and control and HSPB1-/- broblasts. However,
CHAPTER 3. RESULTS 38
the dierence in growth of patient (HSPB14C-term) and HSPB1-/- broblasts
was signicant only at 24 hours time point. The growth curves of all three
cell lines before and after heat shock are shown in Figure 3.6.
Cut-o C0-C30 (A) P0-P30 (B) A \ B
p-value  0.01 50 5 5
p-value  0.01,
-1.75  logFC  1.75 5 5 5
Table 3.3: Numbers of signicantly dierentially expressed genes with dierent cut-o
values between the two comparisons. A represents, response of control (C0-C30), B rep-
resents a response of the patient (P0-P30) and A \ B represents the number of common
genes between two conditions.
Figure 3.4: Relative mRNA level of HSPA6 and DNAJB1 before heat treatment for control
(C), patient (P) and HSPB1-/- (KO). Data normalized to the expression level of control
(C) before heat treatment.
3.7 Analysis of putative transcription factor
binding sites
Since the patient cells and HSPB1-/- cells were sensitive towards heat stress,
but expression levels of heat shock genes (HSPA6 and DNAJB1 ) were similar
to control cells after heat shock, the question was how the growth rate of pa-
tient cells and HSPB1-/- cells were aected? To answer this question, one idea
was to analyse the promoter sequences of up-regulated and down-regulated
dierentially expressed genes. This would allow us to identify putative tran-
scription factor binding sites in promoter region of these genes that might
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co-regulate genes responsible for cell growth.
Figure 3.5: Relative mRNA level of HSPA6 and DNAJB1 after 1 hour of heat treatment
for control (C), patient (P) and HSPB1-/- (KO). Data normalized to the expression level
of control (C) before heat treatment.
Transcription factor motif enrichment analysis through AME and Centrimo
was performed on the experimentally validated promoter sequences of top
up- and down-regulated dierentially expressed genes from both untreated
(P0-C0) and 30 minutes heat treated (P30-C30) conditions independently
as described in Section 2.6. The analysis identied enrichment of possible
binding sites of four transcription factors SP1, SP2, Klf4 and Klf5 within
180 bp distance in the promoter site of down-regulated genes in untreated
samples (P0-C0). However, in the promoter region of upregulated genes both
AME and Centrimo were not able to nd any signicantly enriched motifs
other than a TATA box (TBP), which is common in all promoter sequences.
There were 73 dierentially expressed genes under untreated condition (P0-
C0) and 71 dierentially expressed genes under 30 minute heat treated con-
dition (P30-C30) with 68 genes common between them. As expected, we
observed enrichment of same transcription factor motifs in down-regulated
genes in treated samples (P30-C30) because of the large overlap in dier-
entially expressed genes. The results of the motif enrichment analysis for
untreated (P0-C0) condition is summarized in Table 3.4. The predicted oc-
cupancy site for these four transcription factors within the 600 bp region of
the promoter sequences of down-regulated genes is shown in the Figure A.1.
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.
(a) Growth curve of control,
M169CfsX4 (HSPB14C-term) and
KO (HSPB1-/-) broblasts under
normal condition.
(b) Growth curve of control,
M169CfsX4 (HSPB14C-term)
and KO (HSPB1-/-) broblasts
after 1 hour of heat shock at
45C followed by 24 hours
of recovery under normal
condition.
Figure 3.6: Response of control, patient and HSPB1-/- broblast (a) before and (b) af-
ter heat stress. () represents statistical signicance measured with control and ( )
represents statistical signicance measured with control and between HSPB14C-term and
HSPB1-/- broblast at P  0.01.
ID Name E-value
Region
Center
Region
Matches
MA0516.1 SP2 2.1E-06 107 32
MA0079.3 SP1 1.1E-05 92.5 34
MA0039.2 Klf4 1.5E-03 131 23
MA0599.1 Klf5 2.3E-02 122 25
Table 3.4: Enriched motif in down-regulated genes of samples without heat treatment
(P0-C0) and E-value  1.
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Figure 3.7: Validation of genes on altered pathway using the control (C1) as in the mi-
croarray experiment. The expression changes measured using qPCR were consistent for
all the genes measured.
Figure 3.8: Validation of genes on altered pathway using a control (C2). The expression
changes measured using qPCR were not consistent with the microarray results for all the
genes measured.
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Figure 3.9: Validation of genes on altered pathway using a control (C3). The expression
changes measured using qPCR were not consistent with the microarray results for all the
genes measured.
3.8 qPCR Validation of genes on altered path-
ways
Since the microarray experiment was performed with one patient and one
control sample, the results of pathway analysis and promoter analysis can-
not be generalized without considering the inherent genetic variations across
cultured cells. Thus, 11 genes were randomly selected from top up- and down-
regulated gene list of microarray experiment belonging to dierent pathways
including extracellular matrix proteins. The expression levels of these 11
genes were validated using three dierent control broblasts, one was the
same used in the microarray experiment. Their relative expression levels
were quantied using GAPDH as reference gene, as it had a stable expres-
sion level across dierent control broblasts. The expression levels quantied
using RT-qPCR were consistent with the microarray results when observed
with the same control used in the microarray experiment. However, the ex-
pression levels of selected 11 genes were inconsistent with respect to other two
control broblasts. This could indicate that dierentially expressed genes ob-
served between patient and control cells are not only the downstream eect
of truncated HSPB1 but they could also be caused by other genetic dier-
ences between cultured cells. The expression quantied with respect to three
separate controls are shown in the Figures 3.7, 3.8 and 3.9.
Chapter 4
Discussion
HSPB1 is a ubiquitously expressed multifunctional molecular chaperone that
is known to be involved in a plethora of cellular processes [60]. Although be-
ing ubiquitously expressed, mutations in HSPB1 have been associated with
diseases of peripheral nervous system such as CMT2F and dHMN [60]. For
example, mutations in HSPB1 are associated with increased binding anity
to their client proteins. These increased bindings of CMT-causing HSPB1
mutant to tubulin and microtubules result in reduction of microtubule dy-
namics [4]. Furthermore, mechanism of action of HSPB1 and other sHSPs
attracts attention because of their roles in protein quality control and phys-
iologic processes [10, 41, 58]. For many diseases like neurodegeneration and
cancer, understanding cell survival mechanism in stress is important because
cancer cells can escape drug induced stress by regulating HSPB1 [31]. Sim-
ilarly, HSPB1 overexpression has been found to prevent Parkinson's disease
related protein aggregation [38, 58]. This study focused on characterization
of the molecular consequences of a new neuropathy related HSPB1 variant in
primary patient broblasts. The mutation resulting in truncated HSPB1 pro-
vided an opportunity to study the poorly understood function of C-terminus
of HSPB1 [58]. Several reported missense mutations in HSPB1 have been
studied through overexpression systems in immortalized cell lines and neu-
ronal cells of rodents [1, 3, 4, 53]. In this study, we used primary patient's
broblast, which adds to understanding in vivo consequences of mutant pro-
tein on endogenous level of HSPB1 expression. We were able to show the sta-
bility of truncated HSPB1 suggesting C.505delA mRNA escaped non-sense
mediated decay leading to HSPB14C-term protein. This scenario is possible
if premature stop codon appears in the last exon of a gene [17].
As discussed in Section 1.6, HSPB1 can form oligomers of up to 800 kDa
under normal conditions which are regulated by post translational modi-
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cations (PTMs) [41]. Dimerization is assumed to be the minimal structural
unit of HSPB1 oligomers and occurs through ACD [22, 24, 58]. In the west-
ern blot Figure 3.2, we were not able to detect any bands above 50 kDa
suggesting prevalence of HSPB1 dimers under normal conditions. Further-
more, HSPB14C-term broblasts showed bands corresponding to all possible
combinations of HSPB1 dimers. With this result, we can conclude that
the HSPB14C-term bound to wild type protein can incur a dominant neg-
ative eect, which in turn contributed to neuropathy phenotype through
reduced availability of normal wild type dimers in our patient. In a study
of C-terminal variant of HSPB1P182L, the mutant proteins were also found
to form dimers with wild type HSPB1. Overexpressed HSPB1P182L in some
neurons formed insoluble aggregates [1], which were not present in Figure 3.3
A of our patient broblasts suggesting a dierent pathogenic mechanism in
between truncated and missense variants of C-terminus [58]. Furthermore,
the aggregation of HSPB1P182L mutant in neurons could also be because of
overexpression.
In the Chapter 3, I described nuclear translocation of HSPB1 at high tem-
perature. However, the nuclear role of HSPB1 is unclear. I was able to
demonstrate the translocation of HSPB14C-term protein to the nucleus upon
heat stress, suggesting the decreased heat tolerance of patient cells is not
caused by defective translocation [58]. Moreover, expression of similar genes
in both treated (P30-C30) and untreated (P0-C0) condition of the microarray
experiment and enrichment of pathways like macrophage activation, cellular
defence response, response to stimulus, immune system processes are all ex-
pected as patient broblast with truncated HSPB1 has reduced ability to
respond against stress. Furthermore, heat itself has a denaturing eect on
proteins causing additional stress. Thus, increased expression levels of genes
involved in these pathways provide ideas on how cells are trying to compen-
sate the stress. These results suggest the C-terminal truncation of HSPB1
did not inuence the early heat shock response. However, enrichment of ex-
tracellular matrix proteins was unexpected under both treated and untreated
conditions. This could mean that HSPB1 has an extracellular role or par-
ticipates in signal transduction. Although the extracellular role of HSPB1 is
unclear, few articles have corroborated the fact that the secreted HSPB1 par-
ticipates in chaperoning immunogenic peptides and they were able to detect
extracellular HSPB1 through western blot [33, 47]. Following the protocol of
[33], I was not able to detect a band corresponding to wild type or truncated
HSPB1 from the conditioned medium. This might be because of the low con-
centration of protein in the medium. Furthermore, the secretion of HSPB1
might also be cell type specic as previous ndings were derived from acti-
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vated macrophages and endothelial cells. There are other sensitive methods
to detect secreted proteins from medium such as enzyme-linked immunosor-
bent assay (ELISA), mass spectroscopy (MS), but these analysis were out of
scope for this thesis.
Moreover, RT-qPCR validation of genes on altered pathways revealed some
inconsistencies. As stated before, the microarray experiment was performed
with one patient and one control sample. Although the expression levels of
selected 11 genes measured by RT-qPCR for the same control were consis-
tent with the microarray expression levels, the measurements for the same 11
genes for other two controls did not agree with earlier results. This suggests
the changes in gene expression of patient cells were not entirely because of
the truncated HSPB1 but also other genetic dierences between the cultured
cells, which points to the need for more reliable and genetically homogeneous
control sample, which would reduce the genetic background. One method to
achieve this is to correct the mutation (C.505delA) using CRISPR/Cas9 in
patient broblasts and use it as a control sample.
HSPB1 response to external stresses like heat, oxidative stress, heavy met-
als and ischemia protect cells and also is a general theme of protection of
sHSPs [58]. Heat is a generalized stressor and it causes protein misfolding,
loss of host cell functions, induces cytoskeleton and cell cycle arrest [56, 58].
sHSPs dier from normal heat shock proteins, mainly because these sHSPs
lack ATPase activity, hence cannot actively refold proteins [41]. HSPB1
binds to denatured or misfolded proteins and prevents the formation of toxic
aggregates [10]. Using the HSPB14C-term, HSPB1-/- and control broblasts
we were able to demonstrate signicantly decreased heat tolerance in both
HSPB14C-term and HSPB1-/- broblasts in comparison to control cells, but
growth of HSPB14C-term and HSPB1-/- did not dier signicantly until the
last time point (refer Figure 3.6). With a longer recovery we might be able
to see a dierence but this result suggests reduced dimer formation by a
dominant-negative eect has the same consequence as having no HSPB1 at
all.
Similarly, response of the patient (P0-P30) and response of the control (C0-
C30) to heat shock yielded 5 dierentially expressed genes under both con-
ditions. The genes were coding for proteins that protects cells from stress
(DNAJB1, EGR1, FOS, HSPA6 and HSPA7 ). This result suggests patient
and control broblasts have similar transcriptional heat shock response. Fur-
thermore, there were small changes in the expression of the other 45 genes
that were statistically signicant for response of control to heat shock. Al-
CHAPTER 4. DISCUSSION 46
though these small changes in expression might have large eect in post
mitotic cells, these changes usually have little or no signicance in actively
dividing cells like broblast. Thus, we cannot conclusively assert the fact
that the transcriptional response of patient broblast is dierent than that
of control broblast. To conrm these ndings, it would be interesting to
observe the gene expression proles in neurons derived from the patient and
control broblasts before and after heat stress. In addition to microarray re-
sults, expression levels quantied using qRT-PCR for two of the dierentially
expressed heat shock proteins (DNAJB1 and HSPA6 ) in control, patient
and HSPB1 knockout (HSPB1-/-) broblasts suggest that HSPB1 might not
have any role in the expression of those genes. This is the indication that
C-terminal truncation did not participate in early induction of heat-stress re-
lated genes [58]. Thus, HSPB1 may have a chaperoning function of misfolded
proteins in the nucleus rather than direct involvement in regulation of gene
expression. The reduction in the growth rate of HSPB14C-term broblasts
during extended exposure to heat, might have been caused by denaturation
of proteins responsible for cell growth and cell division, which the truncated
HSPB1 was unable to chaperone [58]. With these results it can be stated
that the C-terminus of HSPB1 is necessary for the protein to maintain its
ability to protect cell against partially denatured, independent of nuclear
translocation [58]. Since the results of microarray experiment and pathway
analysis is based on one patient and one control sample, the statistical power
and biological relevance of the analysis is reduced as an inherent genetic vari-
ability of cultured cells remains unaccounted.
Analysis of the promoter region of down-regulated genes of patient brob-
lasts revealed enrichment of binding sites for transcription factors SP1, SP2,
KLF4 and KLF5. Studies have identied SP1 transcription factor binding
sites at promoter regions of growth related genes providing evidence for its
involvement in cell growth. This function of SP1 was conrmed when trun-
cated SP1 was able to inhibit growth of cells through a dominant negative
mechanism [13]. SP/KLF is family of transcription factors of 20 identied
members with a characteristic zinc nger domain similar to Drosophila pro-
tein, kruppel [13]. SP/KLF factors bind to GC-boxes in DNA with varying
anities and potentially aect \SP1 dependent" transcription [13]. Regula-
tion of members of the SP/KLF family in the developmental phase corrob-
orates its involvement in cell growth and dierentiation [13]. Enrichment of
these transcription factors in the promoters of dierentially expressed down-
regulated genes suggest that, the decreased growth rate of HSPB14C-term
broblasts might have been caused by reduced ability of truncated HSPB1
to chaperone these misfolded transcription factors during heat shock or re-
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duced availability of wild type HSPB1 dimer by a dominant negative eect.
Furthermore, molecular mechanism of KLF transcription factors has been
studied in proliferating cells, but limited is known in post mitotic cells like
neurons where even small changes in steady state concentration of these pro-
teins can have a large eect. One of the noted eects is decreased neurite
outgrowth by expression of KLF4 in hippocampal and cortical neurons [39].
Although our expression results are based on proliferating patient broblast
cells, it would be interesting to study the expression levels of KLF family in
iPSc (induced pluripotent stem cells) derived patient neurons.
Chapter 5
Limitations of the study and fu-
ture work
The major limitation of this study is the small sample size, as only one
HSPB14C-term patient and one HSPB1-/- broblasts were available. The mi-
croarray experiment was based on only one patient and control sample and
that has reduced the statistical power of the analysis in the project. A genet-
ically homogeneous control sample would have reduced the background ex-
pression and would have provided better insight on altered pathway and func-
tionality of C-terminus of HSPB1. Another microarray experiment with con-
trol generated through correction of the truncated mutation using CRISPR
in patient broblast would reduce the genetic background and provide more
accurate ndings. Furthermore, we were able to show that HSPB14C-term is
associated with peripheral neuropathy and impairs heat tolerance of cells, but
more accurate disease models such as iPS cells derived patient neurons are
needed to fully understand the pathogenesis of HSPB1 related neuropathy
[58]. Moreover, more patient samples with same or similar mutations would
allow more extensive testing of the conclusions derived from this study.
It would be interesting to investigate the stress tolerance in neuronal cells
and dierentiated neurons from patient-derived induced pluripotent stem
cells [58]. Since, peripheral motor and sensory neurons are post-mitotic they
are sensitive to small changes in steady state concentration of cellular com-
ponents. Thus, it would also be interesting to test the ndings of promoter
analysis and check the expression level of KLF transcription factor family
specially KLF4 and KLF5 in dierentiated neurons from patient-derived in-
duced pluripotent stem cells.
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Appendix A
Appendix
Gene Primer Sequence (5'! 3')
IL13RA2 F CAATGCTGGGAAGGTGAAGAC
IL13RA2 R TGGGTAGGTGTTTGGCTTACG
ALDH1A3 F AGGGTGGGCAGACAAAATCC
ALDH1A3 R GGGGAAGTTCCATGGAGTGAT
STK32B F GAATATGGGCGGGAACCACT
STK32B R TGCACGATGCATACCTTTCC
COL18A1 F GCCGTGGCATTCCTAGCTC
COL18A1 R CTGATGCGCTCTGAAGATGGT
CLEC14A F GGGATCACAGAGCACGATGT
CLEC14A R CCTGATGGGGTGATAGTGGC
PTGIS F CTGGAGGAGATGGGTGTGTC
PTGIS R GGACCCATATTCCCCTGTGT
LGR4 F GAAGAGCTACAATTGGCGGG
LGR4 R CTCGAATGGCTTCACTGGGT
COL4A1 F ACTCTTTTGTGATGCACACCA
COL4A1 R AAGCTGTAAGCGTTTGCGTA
VEGFC F GAGGCTGGCAACATAACAGAG
VEGFC R CCTTGAGAGAGAGGCACTGT
CRIP1 F AGTAAACCAGGTGGTGGAGAC
CRIP1 R AGCATTAGGGGCAACAAGGG
PCOLCE2 F TAATGGCGGGGAAGTCAACG
PCOLCE2 R AATTGGCGCAGGTGGACTAT
HSPA6 F CAGAGGAACGCCACTATCCC
HSPA6 R ACTGAGTTCAAAACGCCCCA
DNAJB1 F CTGCGCTACCACCCGGAC
DNAJB1 R TTTAGGCCTTCCTCCCCGTAG
Table A.1: Primers designed for the project.
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Figure A.1: Predicted occupancy site of enriched transcription factor in the promoter
region of down-regulated genes from samples without heat treatment (P0-C0).
